| Identification | More | [Name]
1alpha,25-Dihydroxycholecalciferol | [CAS]
32222-06-3 | [Synonyms]
1,25-(OH)2-D3
1A, 25-DIHYDROXYCHOLECALCIFEROL
1ALPHA,25-DIHYDROXYCHOLECALCIFEROL
1ALPHA,25-DIHYDROXYVITAMIN D3
1ALPHA,25-DIHYDROXY-VITAMIN D8
(1ALPHA,3BETA,5Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1,3,25-TRIOL
(5z,7e)-(1s,3r)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
9,10-SECOCHOLESTA-5Z,7E,10(19)-TRIENE-1ALPHA,3BETA,25-TRIOL
CALCITRIOL
VITAMIN D3, 1ALPHA,25-DIHYDROXY
(5z,7e)-9,10-secochesta-5,7,10(19)-triene-1-alpha,3-beta,25-triol
(5z,7e)-9,10-secocholesta-5,7,10(19)-triene-1-alpha,3-beta,25-triol
1,25-dhcc
1,25-dihydroxycholecalciferol
1,25-dihydroxyvitamind
1a,25-dihydroxy-cholecalcifero
1-alpha,25-dihydroxy-cholecalcifero
7,10(19)-triene-1,3,25-triol,(1-alpha,3-beta,5z,7e)-10-secocholesta-5
7,10(19)-triene-1,3,25-triol,(1alpha,3beta,5z,7e)-10-secocholesta-5
9,10seco(5z,7e)-5,7,10(19)-cholestatriene-1alpha,3beta,25-triol | [EINECS(EC#)]
250-963-8 | [Molecular Formula]
C27H44O3 | [MDL Number]
MFCD00867079 | [Molecular Weight]
416.64 | [MOL File]
32222-06-3.mol |
| Chemical Properties | Back Directory | [Appearance]
White Crystalline Powder | [Melting point ]
119-1210C | [alpha ]
D25 +48° (methanol) | [Boiling point ]
474.91°C (rough estimate) | [density ]
1.0362 (rough estimate) | [refractive index ]
1.4700 (estimate) | [Fp ]
14 °C | [storage temp. ]
2-8°C
| [solubility ]
Do you have solubility information on this product that you would like to share | [form ]
Solid | [pka]
14.43±0.40(Predicted) | [color ]
White to Almost white | [Usage]
The biologically active form of vitamin D3. Calcium regulator; vitamin (antirachitic); antihyperparathyroid; antineoplastic; antipsoriatic | [λmax]
265nm(lit.) | [Merck ]
14,1644 | [BRN ]
7559394 | [BCS Class]
2,4 | [Stability:]
Air and Light Sensitive | [InChIKey]
GMRQFYUYWCNGIN-UNVJKIGWSA-N | [CAS DataBase Reference]
32222-06-3(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
T+,Xn | [Risk Statements ]
R26/27/28:Very Toxic by inhalation, in contact with skin and if swallowed .
R63:Possible risk of harm to the unborn child.
R36/37/38:Irritating to eyes, respiratory system and skin .
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . | [Safety Statements ]
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) .
S36:Wear suitable protective clothing .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . | [RIDADR ]
UN 2811 6.1/PG 1
| [WGK Germany ]
3
| [RTECS ]
FZ4645000
| [F ]
8-10-19 | [HazardClass ]
6.1(a) | [PackingGroup ]
I | [HS Code ]
29362900 | [Hazardous Substances Data]
32222-06-3(Hazardous Substances Data) | [Toxicity]
mouse,LD50,intraperitoneal,1900ug/kg (1.9mg/kg),SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYEBEHAVIORAL: ATAXIA,Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 11, Pg. 4175, 1983. |
| Questions And Answer | Back Directory | [Introduction]
Calcitriol (1,25-dihydroxylcholecaldiferol) is a steroid hormone with three hydroxyl groups, which is an active metabolite and the most effective form of vitamin D. It is produced primarily in the kidney when the blood calcium level and parathyroid hormone are low. Calcitriol promotes the calcium and phosphorus absorption in the intestine, reabsorption in the kidneys. Along with parathyroid hormone, it regulates bone growth for building and keeping strong bones. Calcitriol is used to treat and prevent low levels of calcium and bone disease in patients whose kidneys or parathyroid glands are not working normally, to treat secondary hyperparathyroidism and metabolic bone disease in people with kidney disease. Calcitriol may also be chemopreventive for colon and prostate cancers as it induces cell cycle arrest, cell differentiation, and apoptosis.
| [References]
- https://pubchem.ncbi.nlm.nih.gov
- https://medlineplus.gov
- http://flexikon.doccheck.com/en/Calcitriol
- https://en.wikipedia.org/wiki/Calcitriol
- https://www.webmd.com
|
| Hazard Information | Back Directory | [Chemical Properties]
White Crystalline Powder | [Originator]
Rocaltrol,Roche,US,1978 | [Definition]
ChEBI: A hydroxycalciol that is calcidiol in which the pro-S hydrogen of calcidiol is replaced by a hydroxy group. It is the active form of vitamin D3, produced fom calciol via hydoxylation in the li
er to form calcidiol, which is subsequently oxidised in the kidney to give calcitriol. | [Manufacturing Process]
1α,25-Dihydroxyprecholecalciferol: A solution of 1α,25-
diacetoxyprecholecalciferol (0.712 g, 1.42 mmols), potassium hydroxide (2.0
g, 35.6 mmols) and methanol (40 ml) was stirred at room temperature under
argon for 30 hours. The reaction mixture was concentrated under reduced
pressure. Water (50 ml) was added to the residue and the mixture was
extracted with methylene chloride (3 x 100 ml). The combined organic
extracts were washed with saturated sodium chloride solution (3 x 50 ml),
dried over anhydrous sodium sulfate, filtered and evaporated under reduced
pressure to give 0.619 g of 1alpha,25-dihydroxyprecholecalciferol as a thick
oil.
1α,25-Dihydroxycholecalciferol: A solution of 1α,25-dihydroxyprecholecalciferol
[0.619 g in dioxane (30 ml)] was heated under reflux for 30 minutes under an
atmosphere of argon. The reaction mixture was concentrated under reduced pressure and the residue was purified with a Waters Associates liquid
chromatograph model 202 using a 8 foot * 3/8 inch Porasil A column and a
5:1 mixture of ethyl acetate-n-hexane as the eluent to give 0.474 g (80%
yield based on 1α,25-diacetoxyprecholecalciferol) of pure 1α,25-
dihydroxycholecalciferol. Recrystallization from methyl formate afforded 0.340
g of 1α,25-dihydroxcholecalciferol as colorless crystals, MP 113°-114°C. | [Brand name]
Calcijex (Abbott); Rocaltrol (Roche. | [Therapeutic Function]
Calcium regulator | [General Description]
1α,25-Dihydroxyvitamin D3, also referred as calcitriol, is a calcitrophic hormone. It is the most biologically active metabolite of vitamin D produced in proximal tubular cells in the kidney. | [Biological Activity]
Active metabolite of vitamin D 3 that activates the vitamin D receptor (VDR). Displays calcemic actions; stimulates intestinal and renal Ca 2+ absorption and regulates bone Ca 2+ turnover. Exhibits antitumor activity; inhibits in vivo and in vitro cell proliferation in a wide range of cells including breast, prostate, colon, skin and brain carcinomas and myeloid leukemia cells. | [Biochem/physiol Actions]
Biologically active form of vitamin D3 in calcium absorption and deposition. 1α,25-Dihydroxyvitamin D3 has widespread effects on cellular differentiation and proliferation, and can modulate immune responsiveness, and central nervous system function. Recent studies suggest that 1α,25-dihydroxyvitamin D3 acts as a chemopreventive agent against several malignancies including cancers of the prostate and colon and shows synergy with other anticancer compounds. | [Clinical Use]
Vitamin D analogue:
Promotes intestinal calcium absorption
Suppresses PTH production and release | [Veterinary Drugs and Treatments]
Calcitriol may be potentially beneficial in the adjunctive treatment
of chronic renal
disease in dogs and cats but its use is somewhat
controversial, particularly the decision on how soon in the course
of chronic renal insufficiency it should employed. It may also be of
benefit in treating some types of dermatopathies (primary idiopathic
seborrhea). | [Drug interactions]
Potentially hazardous interactions with other drugs
Antiepileptics: the effects of vitamin D may
be reduced in patients taking barbiturates or
anticonvulsants.
Diuretics: increased risk of hypercalcaemia with
thiazides.
Sevelamer: absorption may be impaired by sevelamer | [Metabolism]
During transport in the blood at physiological
concentrations, calcitriol is mostly bound to a specific
vitamin D binding protein (DBP), but also, to a lesser
degree, to lipoproteins and albumin. At higher blood
calcitriol concentrations, DBP appears to become
saturated, and increased binding to lipoproteins and
albumin occurs.
Calcitriol is inactivated in both the kidney and
the intestine, through the formation of a number
of intermediates including the formation of the
1,24,25-trihydroxy derivatives. It is excreted in the bile
and faeces and is subject to enterohepatic circulation. | [storage]
-20°C, protect from light, stored under nitrogen,unstable in solution, ready to use. |
| Questions and Answers (Q&A) | Back Directory | [description]
Calcitriol is the active form of vitamin D and is also a kind of hormones in the body. It plays an important role in the regulation of calcium and phosphorus concentration. It can increase the blood calcium level by increasing the intestinal absorption of calcium and can also increase the release of the bone calcium release for increasing the blood calcium levels. This study was first conducted and reported by Michael F. Holick in 1971. The basic principle of action model of calcitriol in many cases is through binding with the vitamin D receptor (the VDR), e.g., the ligand-receptor complex forming between calcitriol and its receptor in the intestinal epithelial cells cytoplasm can be transferred to the nucleus for being as the transcriptional factor in promoting the expression of calcium-binding protein. The increased level of calcium-binding proteins can help the cell to actively transport of more calcium ions, thereby increasing the calcium absorption level. Calcium absorption while maintaining electrical neutrality also requires transporting anions, mainly the absorption of inorganic phosphate ions, so calcitriol also promote the absorption of phosphorus.
Clinically, this drug can be used in the treatment of hypocalcemia, hypoparathyroidism (adult), osteomalacia, rickets (infants), chronic kidney disease, renal osteodystrophy, osteoporosis, as well as the prevention of glucocorticoid induced osteoporosis.
Calcitriol-dimensional molecular structure
The above information is edited by the chemicalbook of Dai Xiongfeng.
| [Uses]
Vitamin medicines; it can be used for treating the renal bone malnutrition of patients with chronic renal failure;
|
|
|